Researchers at the Federal University of São Paulo (UNIFESP) have identified a potential new pathway to protect neurons from Parkinson’s disease by targeting neuroinflammation rather than dopamine replacement. Published in the journal Neuropharmacology, the study shows that the peptide Ac2-26, derived from the protein Annexin A1, reduces neuronal degeneration in mice by mitigating the inflammatory response that accompanies the disease.
How does the Ac2-26 peptide protect the brain?
The Ac2-26 peptide acts as an anti-inflammatory agent that intervenes before neurons die. Unlike standard treatments that focus on replacing dopamine, this experimental approach targets the inflammatory reaction that affects both dopamine-producing neurons and the surrounding brain cells. According to Cristiane Damas Gil, head of the Department of Morphology and Genetics at the São Paulo School of Medicine (EPM), this strategy offers a defensive layer that prevents cell death. While current treatments like levodopa focus on the symptoms of dopamine deficiency, this peptide aims to address the underlying inflammatory environment of the brain.
Parkinson’s disease is characterized by the loss of neurons that synthesize dopamine. This neurotransmitter is vital for motor control, which is why patients often experience tremors and difficulty walking when these cells degenerate.
Why current Parkinson’s treatments lose effectiveness
Levodopa remains the gold standard for Parkinson’s, yet it comes with significant limitations. Luiz Philipe de Souza Ferreira, a FAPESP scholarship recipient who conducted the research, notes that while levodopa provides marked improvement in early stages, its effectiveness often wanes over time. Long-term use can trigger motor complications and fluctuations in how a patient responds to the drug. This cycle of diminishing returns is exactly why researchers are prioritizing therapies that move beyond simple dopamine precursors to address the broader pathology of the disease.

Biological sex and treatment response
The UNIFESP team discovered distinct differences in how male and female mice respond to the simulated disease. In initial movement tests, female mice showed greater resilience, even in cases where the Annexin A1 protein was absent. Conversely, male mice exhibited more pronounced neuronal loss, which provided a clearer baseline for the researchers to measure the protective effects of the Ac2-26 peptide. Additionally, the study found that inducing Parkinson’s symptoms significantly disrupted the reproductive cycle in female mice, suggesting that the disease’s impact on the endocrine system requires sex-specific clinical protocols.
When reviewing neurodegenerative research, look for studies that distinguish between biological sexes. Hormonal differences often play a significant role in how the brain manages inflammation and cell survival.
What are the next steps for this research?
The current findings demonstrate that the peptide acts as a preventive measure if administered at the onset of damage. The next phase of research, according to Cristiane Damas Gil, will determine if Ac2-26 can actively reverse existing damage caused by Parkinson’s. If successful, this could shift the focus of Parkinson’s care from symptom management to neuroprotection and recovery. As of now, the peptide has not been developed into a commercial medication, and the study remains in the early, experimental stages.

Frequently Asked Questions
- Is there a cure for Parkinson’s disease? No. Currently, there is no cure. Treatments focus on managing motor symptoms through dopamine replacement.
- What is the role of Annexin A1? It is a protein produced naturally in humans and rodents. The peptide Ac2-26 is a fragment of this protein that helps control neuroinflammation.
- Why is neuroinflammation important in Parkinson’s? Inflammation affects the neurons that produce dopamine as well as surrounding brain cells, contributing to the progression of cell death in the disease.
Are you interested in the latest developments in neuroscience? Subscribe to our newsletter for updates on emerging research and clinical breakthroughs.

